Virijević, Marijana (36969618100)Marijana (36969618100)VirijevićMitrović, Mirjana (54972086700)Mirjana (54972086700)MitrovićPantić, Nikola (57221630977)Nikola (57221630977)PantićPravdić, Zlatko (57221636770)Zlatko (57221636770)PravdićSabljić, Nikica (57221634280)Nikica (57221634280)SabljićSuvajdžić-Vuković, Nada (36446767400)Nada (36446767400)Suvajdžić-Vuković2025-06-122025-06-122022https://doi.org/10.2298/VSP210721090Vhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85163408300&doi=10.2298%2fVSP210721090V&partnerID=40&md5=aff7954a8266215a50f8ad9bcd681cb4https://remedy.med.bg.ac.rs/handle/123456789/3713Background/Aim. The availability of thrombopoietin receptor agonists (TPO-RA) for treating primary immune thrombocytopenia (ITP) has transformed its management over the last decade. The aim of this study was to assess the efficacy of TPO-RA in adults with chronic ITP treated at the University Clinical Center of Serbia. Methods. A total of 28 adult ITP patients (10 males and 18 females), who were given eltrombopag and/or romiplostim, were enrolled in the study. Data on demographic characteristics, ITP duration, previous therapeutic modalities, comorbidities, concomitant therapy both for comorbidities and ITP, indications for TPO-RA, bleeding episodes before and during TPO-RA, TPO-RA doses, adverse events, and response rates were collected from the patients’ medical records. TPO-RAs were administered in patients with chronic refractory ITP when splenectomy was contraindicated/unfeasible and as preparation for splenectomy. Favorable treatment response was defined as a stable platelet count ≥ 50 × 109/L. Results. A total of 22 (78.57%) and 14 (50.0%) patients were treated with eltrombopag and romiplostim, respectively. A good treatment response (GTR) was achieved in 81.8% of the patients receiving eltrombopag and 71.4% of those treated with romiplostim. The non-responders to eltrombopag (4 patients) and those who had lost their response to eltrombopag (4 patients) were switched to romiplostim. Six of 8 patients achieved a GTR. At the time of TPO-RA initiation, 46.4% of the patients used concomitant ITP therapy, which was ceased in all those with a GTR. The following adverse effects of TPO-RA were registered: transaminitis and transient ischemic attack for eltrombopag – one patient each, and pulmonary embolism in one romiplostim-treated patient. Conclusion. Our study showed that TPO-RAs are an effective and safe treatment option since the majority of patients achieved stable remission without bleeding episodes. © 2022 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved.eltrombopagidiopathicpurpurareceptors, thrombopoietinromiplostimthrombocytopenictreatment outcome